Uterine Cancer Therapeutics & Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Uterine Cancer Therapeutics & Diagnostics Market Analysis
The Uterine Cancer Therapeutics & Diagnostics Market is expected to witness a growth of 6% CAGR owing to the growing awareness of uterine cancer and increasing healthcare expenditure. In the United States, the month of September is Gynecologic Cancer Awareness Month. The American Association for Cancer Research has stated in its article that endometrial carcinoma is common across the globe whereas, Uterine Sarcoma is considered as a rare type of cancer. CDC has stated that around 68% of the uterine cancers are the endometrial carcinomas.
Furthermore, developing countries like India has a National Cancer Control Programme which was established in 1975-76. This has contributed to the development of Regional Cancer Centres (RCCs), oncology wings in medical colleges and support for the purchase of teletherapy machines. In this country, the awareness programmes about the cancer are being conducted which is making the women aware of the severity of the disease.
Looking at the severity of the disease and importance of the women health, healthcare providers along with the governments are provoking awareness programmes in certain regions such as North America, Europe, and Asia-Pacific. With the growing focus of the government and the healthcare providers, it has been indicated that the market will grow rapidly in the over the forecast period.
Uterine Cancer Therapeutics & Diagnostics Market Trends
This section covers the major market trends shaping the Uterine Cancer Therapeutics & Diagnostics Market according to our research experts:
Endometrial Adenocarcinoma to Witness Highest Growth Over the Forecast Period
Growing burden of endometrial adenocarcinoma is expected to drive the Uterine Cancer Therapeutics & Diagnostics Market in this segment. According to the Cancer.gov, an endometrial adenosarcoma is the most common type of cancer which is found in women and about 80 percent of uterine cancers are adenocarcinomas, and vary in degree of severity.
Increasing obesity among women is considered as the prime factor responsible for the growing incidence of the endometrium carcinoma as around 90% of the uterine cancers affect the endometrium. with the growing incidence of the disease and the rising awareness about the same, it is believed that rapid growth of the segment will occur in the coming future.
North America is Expected to Dominate the Market over the Forecast Period
North America region is believed to dominate the Global Uterine Cancer Therapeutics and Diagnostics Market in the near future. The prime reason for the growth of the market in this region is the rising incidence of the disease and the growing awareness among the general population. American Cancer Society estimates that in 2020, around 65,620 new cases of uterine body cancer in the United States. Furthermore, around 10% of uterine body cancers are sarcoma. In addition, rapid technological advancements in the diagnostics and faster adoption to new technologies in the country are provoking the overall growth of the market studied.
Uterine Cancer Therapeutics & Diagnostics Industry Overview
The market studied is moderately competitive and most of the companies dealing with this market are the global players. However, with the rising technological advancements, smaller companies are also focusing on market penetration and are taking efforts to grab enough market share.
Uterine Cancer Therapeutics & Diagnostics Market Leaders
-
Abbott Laboratories
-
Becton Dickinson and Company
-
Merck & Co., Inc.
-
Takeda Pharmaceutical Company Limited
-
GlaxoSmithKline Plc.
*Disclaimer: Major Players sorted in no particular order
Uterine Cancer Therapeutics & Diagnostics Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Growing Awareness About Uterine Diseases and Their Available Therapies
-
4.2.2 Increasing Health Care Expenditure
-
4.2.3 Innovation in Drug Development and Subsequent Technological Advancements
-
-
4.3 Market Restraints
-
4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs
-
4.3.2 High Cost Associated With the Treatment
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Cancer Type
-
5.1.1 Endometrial Adenocarcinoma
-
5.1.2 Adenosquamous Carcinoma
-
5.1.3 Papillary Serous Carcinoma
-
5.1.4 Uterine Sarcoma
-
-
5.2 By Product
-
5.2.1 Therapeutics
-
5.2.1.1 Surgery
-
5.2.1.2 Immunotherapy
-
5.2.1.3 Radiation Therapy
-
5.2.1.4 Chemotherapy
-
5.2.1.5 Others
-
-
5.2.2 Diagnostics
-
5.2.2.1 Biopsy
-
5.2.2.2 Pelvic Ultrasound
-
5.2.2.3 Hysteroscopy
-
5.2.2.4 Dilation and Curettage
-
5.2.2.5 CT Scan
-
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
5.3.2 Europe
-
5.3.2.1 Germany
-
5.3.2.2 United Kingdom
-
5.3.2.3 France
-
5.3.2.4 Italy
-
5.3.2.5 Spain
-
5.3.2.6 Rest of Europe
-
-
5.3.3 Asia Pacific
-
5.3.3.1 China
-
5.3.3.2 Japan
-
5.3.3.3 India
-
5.3.3.4 Australia
-
5.3.3.5 South Korea
-
5.3.3.6 Rest of Asia-Pacific
-
-
5.3.4 Middle East and Africa
-
5.3.4.1 GCC
-
5.3.4.2 South Africa
-
5.3.4.3 Rest of Middle East and Africa
-
-
5.3.5 South America
-
5.3.5.1 Brazil
-
5.3.5.2 Argentina
-
5.3.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Ariad Pharmaceuticals, Inc.
-
6.1.2 Abbott Laboratories
-
6.1.3 Becton, Dickinson & Co.
-
6.1.4 GlaxoSmithKline Plc
-
6.1.5 Merck & Co., Inc.
-
6.1.6 Novartis AG
-
6.1.7 Sanofi
-
6.1.8 Siemens Healthcare Inc.
-
6.1.9 Roche Ltd
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Uterine Cancer Therapeutics & Diagnostics Industry Segmentation
As per the scope of the report, uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. The market is segmented by type of cancer, therapeutics, diagnostics and geography.
| By Cancer Type | |
| Endometrial Adenocarcinoma | |
| Adenosquamous Carcinoma | |
| Papillary Serous Carcinoma | |
| Uterine Sarcoma |
| By Product | |||||||
| |||||||
|
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Uterine Cancer Therapeutics & Diagnostics Market Research FAQs
What is the current Uterine Cancer Therapeutics & Diagnostics Market size?
The Uterine Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 6% during the forecast period (2024-2029)
Who are the key players in Uterine Cancer Therapeutics & Diagnostics Market?
Abbott Laboratories, Becton Dickinson and Company, Merck & Co., Inc., Takeda Pharmaceutical Company Limited and GlaxoSmithKline Plc. are the major companies operating in the Uterine Cancer Therapeutics & Diagnostics Market.
Which is the fastest growing region in Uterine Cancer Therapeutics & Diagnostics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Uterine Cancer Therapeutics & Diagnostics Market?
In 2024, the North America accounts for the largest market share in Uterine Cancer Therapeutics & Diagnostics Market.
What years does this Uterine Cancer Therapeutics & Diagnostics Market cover?
The report covers the Uterine Cancer Therapeutics & Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Uterine Cancer Therapeutics & Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Uterine Cancer Therapeutics & Diagnostics Industry Report
Statistics for the 2024 Uterine Cancer Therapeutics & Diagnostics market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Uterine Cancer Therapeutics & Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
